Literature DB >> 18650977

Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension.

Chihiro Shikata1, Tetsuaki Sekikawa, Nobuaki Kimura, Akira Kojima, Shingo Seki, Hisayoshi Oka, Akihiro Nishiyama, Nobuakira Takeda.   

Abstract

BACKGROUND: Cardiac hypertrophy and failure are major complications of hypertension.
OBJECTIVES: The beneficial effect of treatment with antihypertensive drugs on serum levels of brain natriuretic peptide (BNP) was examined in patients with essential hypertension.
METHODS: Antihypertensive drugs were administered to 88 hypertensive patients (44 diabetic and 44 nondiabetic) whose systolic blood pressure was greater than 140 mmHg and/or diastolic blood pressure was greater than 90 mmHg. Other antihypertensive drugs were added every two months until the blood pressure fell below 130/85 mmHg. Candesartan, benidipine, bisoprolol or celiprolol, and bunazosin were administered in this order.
RESULTS: The mean systolic blood pressure was reduced from 163.7+/-11.6 mmHg to 121.8+/-7.5 mmHg after 12 months in patients with diabetes and from 167.6+/-12.3 mmHg to 122.8+/-7.5 mmHg in patients without diabetes. The mean diastolic blood pressure was also significantly reduced in patients with and without diabetes. Serum BNP levels were reduced from 52.2+/-38.8 pg/mL to 38.8+/-30.9 pg/mL in patients with diabetes and from 47.1+/-34.2 pg/mL to 35.8+/-22.5 pg/mL in patients without diabetes. In patients older than 70 years of age, serum BNP levels were reduced from 56.3+/-39.3 pg/mL to 40.2+/-23.0 pg/mL in those with diabetes and from 54.6+/-32.9 pg/mL to 38.0+/-16.0 pg/mL in those without diabetes.
CONCLUSIONS: These results indicate that combination therapy with antihypertensive drugs is usually necessary to reduce blood pressure to below 130/85 mmHg and to improve serum BNP levels.

Entities:  

Keywords:  Angiotensin II receptor blocker; Brain natriuretic peptide; Calcium antagonist; Combination therapy; Hypertension

Year:  2007        PMID: 18650977      PMCID: PMC2359624     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  34 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.

Authors:  B M Psaty; N L Smith; D S Siscovick; T D Koepsell; N S Weiss; S R Heckbert; R N Lemaitre; E H Wagner; C D Furberg
Journal:  JAMA       Date:  1997-03-05       Impact factor: 56.272

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 4.  Preserving target-organ function with candesartan cilexetil in patients with hypertension.

Authors:  F Zannad
Journal:  Blood Press Suppl       Date:  2000

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.

Authors:  J W Eriksson; P A Jansson; K Foley; H Lithell
Journal:  J Hypertens       Date:  1996-12       Impact factor: 4.844

7.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

Authors:  P Lechat; S Escolano; J L Golmard; H Lardoux; S Witchitz; J A Henneman; B Maisch; M Hetzel; P Jaillon; J P Boissel; A Mallet
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

8.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.

Authors:  M R Cowie; A D Struthers; D A Wood; A J Coats; S G Thompson; P A Poole-Wilson; G C Sutton
Journal:  Lancet       Date:  1997-11-08       Impact factor: 79.321

Review 9.  Functional consequences of cardiac hypertrophy and dilatation.

Authors:  R Jacob; M Brändle; B Dierberger; H Rupp
Journal:  Basic Res Cardiol       Date:  1991       Impact factor: 17.165

10.  Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes.

Authors:  P Trenkwalder; K Dahl; M Lehtovirta; H Mulder
Journal:  Blood Press       Date:  1998-05       Impact factor: 2.835

View more
  2 in total

1.  Synergic effects of levamlodipine and bisoprolol on blood pressure reduction and organ protection in spontaneously hypertensive rats.

Authors:  Yan-Ling Yang; Li-Ting Yu; Zhao-Tang Wu; Jian-Guang Yu; Jing-Ming Zhang; Qing-Hua Chen; Yong-Chu Bao; Jian-Guo Liu
Journal:  CNS Neurosci Ther       Date:  2012-06       Impact factor: 5.243

2.  A "patient-tailored" treatment of hypertension with use of impedance cardiography: a randomized, prospective and controlled trial.

Authors:  Paweł Krzesiński; Grzegorz Gerard Gielerak; Jarosław Józef Kowal
Journal:  Med Sci Monit       Date:  2013-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.